Literature DB >> 20536273

An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis.

Rosita Saraceno1, Andrea Chiricozzi, Steven Paul Nisticò, Sergio Tiberti, Sergio Chimenti.   

Abstract

INTRODUCTION: Prurigo nodularis is a distressing condition characterized by the presence of multiple nodules associated with intense pruritus.
OBJECTIVE: To assess the clinical efficacy and safety of betamethasone valerate 0.1% tape and a moisturizing itch-relief cream in prurigo nodularis.
METHODS: Twelve patients were enrolled in this pilot comparison of betamethasone valerate 0.1% tape versus a moisturizing itch-relief cream containing feverfew. The study period was 4 weeks. Clinical evaluation was performed weekly.
RESULTS: Eleven subjects completed the 4 weeks of therapy. The mean visual analogue scale (VAS) for pruritus at baseline was 8.75 for both sides of the body. The side treated with betamethasone valerate 0.1% tape showed a higher clinical response (VAS score at week 4: 3.9; p < 0.005) compared with the side treated with moisturizing itch-relief cream (VAS score at week 4: 5.6; p < 0.005).
CONCLUSION: Both treatments were effective. However, the occlusive dressing enhanced the efficacy of the treatment, preventing scratching.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536273     DOI: 10.3109/09546630903386606

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  10 in total

1.  [56-year-old male with erythematous, excoriated papules and nodules on the extremities, shoulders and buttocks : Preparation for the specialist examination: part 12].

Authors:  Vincent Hoffmann; Claudia Zeidler; Sonja Ständer
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 2.  [New treatment options for chronic pruritus].

Authors:  C Zeidler; B Pfleiderer; S Ständer
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751

3.  [Chronic prurigo].

Authors:  M P Pereira; T Nau; C Zeidler; S Ständer
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

4.  [Therapy of prurigo nodularis].

Authors:  C Zeidler; S Ständer
Journal:  Hautarzt       Date:  2014-08       Impact factor: 1.198

Review 5.  Role of betamethasone valerate 2.250 mg medicated plaster in the treatment of psoriasis and other dermatological pathologies: a review.

Authors:  Sandra Ly; Jean Michel Amici
Journal:  Drugs Context       Date:  2018-08-20

6.  Chronic Pruritus Responding to Dupilumab-A Case Series.

Authors:  Lisa L Zhai; Kevin T Savage; Connie C Qiu; Annie Jin; Rodrigo Valdes-Rodriguez; Nicholas K Mollanazar
Journal:  Medicines (Basel)       Date:  2019-06-29

7.  Efficacy of a Topical Product Containing Purified Omental Lipids and Three Anti-Itching Compounds in the Treatment of Chronic Pruritus/Prurigo Nodularis in Elderly Subjects: A Prospective, Assessor-Blinded, 4-Week Trial with Transepidermal Water Loss and Optical Coherence Tomography Assessments.

Authors:  Marco Ardigò; Chiara Franceschini; Elena Campione; Terenzio Cosio; Caterina Lanna; Luca Bianchi; Massimo Milani
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-12-30

8.  Corticosteroid transdermal delivery to target swelling, edema and inflammation following facial rejuvenation procedures.

Authors:  T Iannitti; V Rottigni; B Palmieri
Journal:  Drug Des Devel Ther       Date:  2013-09-26       Impact factor: 4.162

9.  Targeting PRPK and TOPK for skin cancer prevention and therapy.

Authors:  Eunmiri Roh; Mee-Hyun Lee; Tatyana A Zykova; Feng Zhu; Janos Nadas; Hong-Gyum Kim; Ki Beom Bae; Yan Li; Yong Yeon Cho; Clara Curiel-Lewandrowski; Janine Einspahr; Sally E Dickinson; Ann M Bode; Zigang Dong
Journal:  Oncogene       Date:  2018-06-14       Impact factor: 9.867

10.  Multiple skin ulceration and itch-scratch cycle in a diabetic patient.

Authors:  Satoshi Murao; Kazutoshi Murao
Journal:  J Diabetes Investig       Date:  2021-05-08       Impact factor: 4.232

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.